In collaboration with the group of Dr. F. Munell (Pediatric Neurology), we evaluated a gene therapy strategy for congenital muscular dystrophy 1A based on non-integrative adenoviral vectors targeting the liver. Also, in collaboration with Dr. J. Verdaguer and Marta Corral (U. of Lleida), we investigated a series of new activities and applications of a family of bioactive peptides derived from intermediate filaments. A group member (Penelope Romero) defended her PhD thesis entitled "Development of novel therapeutic strategies for muscular dystrophies”.

Group Leader
Jordi Barquinero Mañez

Principal Investigator (PI)
Jordi Barquinero Máñez

PhD Students
Rocío Piñera Moreno, Penélope Romero Duque, María Gallego Rodríguez (Master TFM student)

2

PUBLICATIONS

50.0%

%Q1

12

IMPACT FACTOR

6.14

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Galiñanes M, Casós K, Blasco-Lucas A, Permanyer E, Máñez R, Le Tourneau T, Barquinero J, Schwartz S Jr, Roussel TBJC, Fellah-Hebia I, Sénage T, Evangelista A, Badano LP, Ruiz-Majoral A, Galli C, Padler-Karavani V, Soulillou JP, Vidal X, Cozzi E, Costa C.
Oxidative Stress in Structural Valve Deterioration: A Longitudinal Clinical Study
Biomolecules. 2022 Oct 31;12(11):1606
DOI: doi: 10.3390/biom12111606
IF: 6.064

Cuenca S, Soler Z, Serrano-Gómez G, Xie Z, Barquinero J, Roca J, Sirvent JM, Manichanh C
Dysbiosis: An Indicator of COVID-19 Severity in Critically Ill Patients
Int J Mol Sci. 2022 Dec 13;23(24):15808
DOI: doi: 10.3390/ijms232415808
IF: 6.208

Development of a novel gene therapy strategy and clinical trial readiness of a cohort of patients with merosin-deficient congenital muscular dystrophy
Principal Investigator: Jordi Barquinero / Francina Munell
Agency: Instituto de Salud Carlos III
Funding: 139,915 €
Period: 2020-2022

eCOREs